Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) CFO Sells $15,552.56 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 6,374 shares of the company’s stock in a transaction dated Thursday, May 8th. The shares were sold at an average price of $2.44, for a total transaction of $15,552.56. Following the sale, the chief financial officer now owns 303,328 shares of the company’s stock, valued at approximately $740,120.32. The trade was a 2.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Austin Aerts also recently made the following trade(s):

• On Thursday, March 6th, Austin Aerts sold 540 shares of Sera Prognostics stock. The shares were sold at an average price of $4.16, for a total transaction of $2,246.40.

Sera Prognostics Stock Up 4.7%

NASDAQ SERA opened at $2.22 on Monday. The company has a 50-day simple moving average of $3.48 and a two-hundred day simple moving average of $5.49. Sera Prognostics, Inc. has a 12-month low of $2.10 and a 12-month high of $9.91. The firm has a market cap of $83.61 million, a price-to-earnings ratio of -2.24 and a beta of 0.99.

Sera Prognostics (NASDAQ:SERA) last posted its earnings results on Wednesday, May 14th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.06 million. Equities analysts expect that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Institutional Trading of Sera Prognostics

A number of institutional investors have recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in shares of Sera Prognostics during the first quarter worth about $39,000. Perkins Capital Management Inc. purchased a new stake in shares of Sera Prognostics during the first quarter worth about $522,000. Bank of New York Mellon Corp boosted its holdings in shares of Sera Prognostics by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 135,582 shares of the company’s stock worth $499,000 after purchasing an additional 4,670 shares during the period. Sanders Morris Harris LLC boosted its holdings in shares of Sera Prognostics by 4.0% during the first quarter. Sanders Morris Harris LLC now owns 94,200 shares of the company’s stock worth $347,000 after purchasing an additional 3,600 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Sera Prognostics by 10.7% during the first quarter. Rhumbline Advisers now owns 39,970 shares of the company’s stock worth $147,000 after purchasing an additional 3,869 shares during the period. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.